The starting line for COVID-19 vaccine development
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Developing a safe and effective COVID-19 vaccine is a global priority to end this pandemic. In their dose-escalation, single-centre, open-label, phase 1 trial published in The Lancet, Feng-Cai Zhu and colleagues1 report the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine, which expresses the full length spike glycoprotein of the Wuhan-Hu-1 strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 108 healthy adults who had not been exposed to SARS-CoV-2, aged between 18 and 60 years (mean age 36·3 years, 49% female), were sequentially enrolled to receive the low, middle, or high dose of the vaccine, given as an intramuscular injection, and observed for 28 days. At around 14 days, neutralising antibodies were detectable with live virus or pseudovirus neutralisation assays, in addition to binding antibodies (to receptor binding domain, spike glycoprotein) measured by ELISA. Dose-dependent antibody responses peaked at 28 days, with seroconversion (>four-fold increase in neutralising antibody titre) documented in 50–75% of participants in the middle and high dose groups. Further, specific T-cell responses toward the spike glycoprotein were shown by interferon (IFN) ? enzyme-linked immunospot, and flow-cytometry (assessing CD4+ and CD8+, IFN?, tumour necrosis factor ?, interleukin-2). Dose-dependent responses were detectable starting from 14 days in 83–97% of participants. The most commonly reported systemic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain (18 [17%]), which were generally mild to moderate in severity, although more frequent in the high dose group.
The Lancet , commentaire en libre accès, 2019